EGUALEN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H18O3S
Molecular Weight	278.367
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C

InChI

InChIKey=NARQSHREEUXZBT-UHFFFAOYSA-N

InChI=1S/C15H18O3S/c1-4-11-9-15(19(16,17)18)14-8-12(10(2)3)6-5-7-13(11)14/h5-10H,4H2,1-3H3,(H,16,17,18)

HIDE SMILES / InChI

Molecular Formula	C15H18O3S
Molecular Weight	278.367
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973

Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing TXA2 production.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
thromboxane A2 signaling pathway 5 Target ID: GO:0038193 Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973	Antagonist 2849
gastric mucosal blood circulation 6 Target ID: GO:1990768 Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973	Activator 1447
mucus secretion 8 Target ID: GO:0070254 Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 74 Sources: http://www.eisai.com/news/enews201620pdf.pdf	Primary		Approved 8583	AZULOXA Approved Use Unknown

C_max

Value	Dose	Analyte	Population
1272 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1417.7 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.6 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.58 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.84 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
10744.1 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11710.9 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
6 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.2 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
18.2 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
7.8 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.7% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=25 \| https://www.jstage.jst.go.jp/article/dmpk1986/5/3/5_3_375/_article/-char/en			EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.2% OTHER GOV'T https://www.jstage.jst.go.jp/article/dmpk1986/5/3/5_3_375/_article/-char/en	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:		EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
1.2 g 1 times / day multiple, oral Highest studied dose Dose: 1.2 g, 1 times / day Route: oral Route: multiple Dose: 1.2 g, 1 times / day Sources: https://www.giejournal.org/article/S0016-5107(13)00893-6/fulltext	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://www.giejournal.org/article/S0016-5107(13)00893-6/fulltext	Sources: https://www.giejournal.org/article/S0016-5107(13)00893-6/fulltext

PubMed

Title	Date	PubMed
A ring expansion-annulation strategy for the synthesis of substituted azulenes. Preparation and Suzuki coupling reactions of 1-azulenyl triflates.	2001-04-05	11277800
Inhibitory effect of egualen sodium: a new stable derivative of azulene on histamine release from mast cell-like cells in the stomach.	2001	11729358

Sample Use Guides

In Vivo Use Guide

1 tablet (15 mg) or 0.6 g of 2.5% granules twice a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:29:50 GMT 2025` Edited by `admin` on `Mon Mar 31 18:29:50 GMT 2025`
Record UNII	17VM9WN49U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EGUALEN

Official Name

English

Egualen [WHO-DD]

Preferred Name

English

egualen [INN]

Common Name

English

3-ETHYL-7-ISOPROPYL-1-AZULENESULFONIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29698